ISSN: 1859 - 2872
Role of interim 18F-FDG PET/CT after 2 cycles of ABVD chemotherapy in Hodgkin lymphoma’s patients
Main Article Content
Keywords
Abstract
Objective: To evaluate role of interim PET/CT after 2 cycles of ABVD chemotherapy in patients with Hodgkin lymphoma. Subject and method: The study was carried out retrospective and prospective descriptive study on 79 patients at Tan Trieu K Hospital from March 2020 to June 2023. Patients were examined clinically, subclinically, had a CT scan or PET/CT film pre-treatment, then received ABVD chemotherapy after 2 cycles of being taken and evaluated interim PET/CT to assess early response according to Deauville score (DS) scale and choose the next chemotherapy to continued treatment based on the guideline of NCCN and follow-up. Result: In a total of 79 patients, common age, male/female: 1/1.3, mean age 32 ± 13.8 (youngest age 8 years old, oldest age 69 years old). Total 54 patients (68.4%) had CT scan and 25 patients (31.6%) had base PET/CT scan pre-treatment. 30.4% had 2 lymph node areas and 28.6 patients had 3 lymph node areas on the body, lymph nodes above the diaphragm 67.9% and lymph nodes both above and below the diaphragm, 49 patients had lymph nodes short-axis average diameter of lymph nodes 27.10 ± 8.3mm. Mediastinum lesion in 19 patients (24.1%) and spleen lesion in 9 patients. Patients with early stage I-II accounted for 82.1%, advanced stage III-IV accounted for 17.9%. After 2 cycles of ABVD chemotherapy, the response rate on PET/CT was iPET/CT2 (-) 63/79 patients (79.7%, of which Deuville score 1 point 90.5%) and iPET/CT2 (+) in 16/79 patients (20.3% of which Deuville score 4 point 87.5). The prognostic index of IPS low-risk group (0-2) complete response (CMR) 88.1%. In the high-risk group IPS (4-7) partial metabolic response (PMR) and no metabolic response (NMR) was 53.8% according to Lugano classification. The Progression-free survival (PFS) of the iPET/CT2 group (-) after 12 and 24 months was 96.8% and 95.2%; PFS of iPET/CT2 group (+) after 12 and 24 months was 87.5% and 81.25%. Conclusion: Interim PET/CT has an important role in providing prognostic information in the treatment of ABVD chemotherapy in HL patients, reducing the toxicity of chemotherapy and orienting the next treatment modality.
Article Details
References
2. Bộ môn Ung Thư (2015) Bệnh Hodgkin, Ung thư học. Trường Đại học Y Hà Nội, Nhà xuất bản Y học, tr. 294-302.
3. Cheson BD (2015) Staging and response assessment in lymphomas: The new Lugano classification. Chinese clinical oncology 4(1): 5-5.
4. Seshachalam A, Karpurmath SV, Rathnam K, Raman SG, Janarthinakani M, Prasad K & Shewade, HD (2019) Does interim PET scan after 2 cycles of ABVD predict outcome in Hodgkin lymphoma? Real-world evidence. Journal of global oncology 5: 1-13.
5. Al-Ibraheem A, Anwer F, Juweid ME, Shagera QA, Khalaf AN, Obeidat S & Mansour A (2022) Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin’s Lymphoma. Scientific Reports 12(1): 17702.
6. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Hodgkin Lymphoma, 5. (2023).
7. Gallamini A, Barrington SF, Biggi A et al (2014) The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica 99(6): 1107–1113.
8. Cerci JJ, Pracchia LF, Linardi CCG et al (2010) 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced hodgkin lymphoma. J Nucl Med 51(9): 1337-1343.
Article Sidebar
